Allosteric Inhibitors of Hepatitis C NS5B Polymerase
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 9 2115
Francesco, R.; Migliaccio, G. Challenges and successes in developing
new therapies for hepatitis C. Nature 2005, 436, 953-960.
(15) (a) Carroll, S. S.; Olsen, D. B. Nucleoside analog inhibitors of
hepatitis C virus replication. Infectious Disorders: Drug Targets
2006, 6, 17-29. (b) Yan, S.; Appleby, T.; Gunic, E.; Shim, J. H.;
Tasu, T.; Kim, H.; Rong, F.; Chen, H.; Hamatake, R.; Wu, J. Z.;
Hong, Z.; Yao, N. Isothiazoles as active-site inhibitors of HCV NS5B
polymerase. Bioorg. Med. Chem. Lett. 2007, 17, 28-33.
temperature for 0.5 h, during which time an oil separated, the
mixture was acidified with concentrated aqueous HCl to pH 3 and
extracted with ether twice. The organic layer was dried over MgSO4,
filtered, and concentrated in Vacuo to give the desired product as
1
a light brown solid 630 mg (75%). H NMR (400 MHz, DMSO-
d6) δ 11.8 (s, 1H), 11.3 (bs, 1H), 8.82 (d, 1H, J ) 9 Hz), 8.13 (dd,
1H, J ) 1.6, 8 Hz), 7.63 (dt, 1H, J ) 1.6, 8 Hz), 7.22 (m, 2H),
6.94 (d, 2H, J ) 9 Hz), 6.86 (d, 1H, J ) 9 Hz), 4.83 (q, 1H, J )
6.8 Hz), 1.69 (s, 3H, J ) 6.8 Hz); HRMS: calcd for C16H14ClNO4
+ H+, 320.06841; found (ESI-FTMS, [M + H]+), 320.06847.
(16) (a) Koch, U.; Narjes, F. Allosteric inhibition of the hepatitis C virus
NS5B RNA dependent RNA polymerase. Infect. Disord.: Drug
Targets 2006, 6, 31-41. (b) Beaulieu, P. L. The discovery of finger
loop inhibitors of the hepatitis C virus NS5B polymerase: status and
prospects for novel HCV therapeutics. IDrugs 2006, 9, 39-43.
(17) (a) Gopalsamy, A.; Shi, M.; Ciszewski, G.; Park, K.; Ellingboe, J.
W.; Orlowski, M.; Feld, B.; Howe, A. Y. M. Design and synthesis
of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta-
[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus
NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett.
2006, 16, 2532-2534. (b) Gopalsamy, A; Aplasca, A.; Ciszewski,
G.; Park, K.; Ellingboe, J. W.; Orlowski, M.; Feld, B; Howe, A. Y.
M. Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]-
pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as
non-nucleoside inhibitors of HCV NS5B RNA dependent RNA
polymerase. Bioorg. Med. Chem. Lett. 2006, 16, 457-460. (c)
Gopalsamy, A.; Lim, K.; Ciszewski, G.; Park, K.; Ellingboe, J. W.;
Bloom, J.; Insaf, S.; Upeslacis, J.; Mansour, T. S.; Krishnamurthy,
G.; Damarla, M.; Pyatski, Y.; Ho, D.; Howe, A. Y. M.; Orlowski,
M.; Feld, B.; O’Connell, J. Discovery of Pyrano[3,4-b]indoles as
Potent and Selective HCV NS5B Polymerase Inhibitors. J. Med.
Chem. 2004, 47, 6603-6608. (d) Gopalsamy, A.; Lim, K.; Ellingboe,
J. W.; Krishnamurthy, G.; Orlowski, M.; Feld, B.; van Zeijl, M.;
Howe, A. Y. M. Identification of [(naphthalene-1-carbonyl)-amino]-
acetic acid derivatives as nonnucleoside inhibitors of HCV NS5B
RNA dependent RNA polymerase. Bioorg. Med. Chem. Lett. 2004,
14, 4221-4224.
(18) Gopalsamy, A.; Chopra, R.; Lim, K.; Ciszewski, G.; Shi, M.; Curran,
K. J.; Sukits, S. F.; Svenson, K.; Bard, J.; Ellingboe, J. W.; Agarwal,
A.; Krishnamurthy, G.; Howe, A. Y. M.; Orlowski, M.; Feld, B.;
O’Connell, J.; Mansour, T. S. Discovery of proline sulfonamides as
potent and selective hepatitis C virus NS5b polymerase inhibitors.
evidence for a new NS5b polymerase binding site. J. Med. Chem.
2006, 49, 3052-3055.
(19) (a) Powers, J. P.; Piper, D. E.; Li, Y.; Mayorga, V.; Anzola, J.; Chen,
J. M.; Jaen, J. C.; Lee, G.; Liu, J.; Peterson, M. G.; Tonn, G. R.; Ye,
Q.; Walker, N. P. C.; Wang, Z. SAR and mode of action of novel
non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J.
Med. Chem. 2006, 49, 1034-1046. (b) Pfefferkorn, J. A.; Greene,
M. L.; Nugent, R. A.; Gross, R. J.; Mitchell, M. A.; Finzel, B. C.;
Harris, M. S.; Wells, P. A.; Shelly, J. A.; Anstadt, R. A.; Kilkuskie,
R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5B
polymerase. Part 1: Evaluation of the southern region of (2Z)-2-
(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. Bioorg. Med. Chem.
Lett. 2005, 15, 2481-2486. (c) Pfefferkorn, J. A.; Nugent, R.; Gross,
R. J.; Greene, M.; Mitchell, M. A.; Reding, M. T.; Funk, L. A.;
Anderson, R.; Wells, P. A.; Shelly, J. A.; Anstadt, R.; Finzel, B. C.;
Harris, M. S.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J.
Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the
northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic
acid. Bioorg. Med. Chem. Lett. 2005, 15, 2812-2818.
Acknowledgment. The authors wish to thank Drs. David
Shlaes and Janis Upeslacis for their support and encouragement
and Dr. Natasja Brooijmans for the critical review of the crystal
structures. We also would like to thank the members of the
Wyeth Chemical Technologies group for analytical and spectral
determinations.
Supporting Information Available: Additional synthetic pro-
cedures and characterization data. This material is available free
References
(1) Matsuura, Y. Expression and characterization of hepatitis C virus
(HCV) proteins. Uirushu 1995, 45, 105-115.
(2) Farci, P.; Alter. J. H.; Shimoda, A.; Govindarajan, S.; Cheung, L.
C.; Melpolder, J. C.; Sacher, R. A.; Shih, J. W.; Purcell, R. H.
Hepatitis C virus-associated fulminant hepatic failure. N. Engl. J.
Med. 1996, 335, 631-634.
(3) Hoofnagle, J. H. Hepatitis Csthe clinical spectrum of disease.
Hepatology 1997, 26, S15-S20.
(4) McHutchison. J. G. Understanding hepatitis C. Am. J. Manag. Care
2004, 10, S21-29.
(5) National Institutes of Health Consensus Development Conference
Panel. National Institutes of Health Consensus Development Confer-
ence Panel statement: management of hepatitis C. Hepatology 1997,
26(suppl 1), 2S-10S.
(6) Alter, M. J.; Kruszon-Moran, D.; Nainan, O. V.; McQuillan, G. M.;
Gao, F.; Moyer, L. A.; Kaslow, R. A.; Margolis, H. S. The prevalence
of hepatitis C virus infection in the United States, 1988 through 1994.
N. Engl. J. Med. 1999, 341, 556-562.
(7) Tan, S.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics:
Current status and emerging strategies. Nat. ReV. Drug DiscoVery
2002, 11, 867-881.
(8) McHutchison, J. G.;. Gordon, S. C; Schiff, E.R.; Shiffman, M. L.;
Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M.; Cort, S.;
Albrecht, J. K. Interferon alfa-2b alone or in combination with
ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med.
1998, 339, 1485-1492.
(9) Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.;
Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.;
Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic
hepatitis C: a randomised trial. Lancet 2001, 358, 958-965.
(10) Asahina, Y.; Izumi, N.; Enomoto, N.; Kurosaki, M.; Onuki, Y.;
Nishimura, Y.; Ueda, K.; Tsuchiya, K.; Nakanishi, H.; Kitamura,
T.; Miyake, S. Mutagenic effects of ribavirin and response to
interferon/ ribavirin combination therapy in chronic hepatitis C. J.
Hepatol. 2005, 43, 623-629.
(11) Dixit, N. M.; Perelson. The metabolism, pharmacokinetics and
mechanisms of antiviral activity of ribavirin against hepatitis C virus.
Cell Mol. Life Sci. 2006, 63, 832-842.
(12) (a) Pawlotsky, J.; McHutchison, J. G. Hepatitis C. Development of
new drugs and clinical trials: promises and pitfalls. Summary of an
AASLD Hepatitis Single Topic Conference, Chicago, IL, February
27-March 1, 2003. (b) Nakagawa, S.; Umehara, T.; Matsuda, C.;
Kuge, S.; Sudoh, M.; Kohara. M. Hsp90 inhibitors suppress HCV
replication in replicon cells and humanized liver mice. Biochem.
Biophys. Res. Commun. 2007. 353. 882-888.
(13) McHutchison, J. G.; Manns, M.; Keyur, P.; Poynard, T.; Lindsay,
K. L.; Trepo, C.; Dienstag, J.; Lee, W. M.; Mak, C.; Garaud, J.;
Albrect, J. K. Adherence to combination therapy enhances sustained
response in genotype-1-infected patients with chronic hepatitis C.
Gastroenterology 2002, 123, 1061-1069.
(14) (a) Gordon, C. P.; Keller, P. A. Control of hepatitis C: A medicinal
chemistry perspective. J. Med. Chem. 2005, 48, 1-20. (b) De
(20) Sugasawa, T.; Toyoda, T.; Adachi, M.; Sasakura, K. Aminohalobo-
rane in organic synthesis. 1. Specific ortho substitution reaction of
anilines. J. Am. Chem. Soc. 1978, 100, 4842-4852.
(21) Rao, A. V. R.; Gaitonde, A. S.; Prakash, K. R. C.; Rao, S. P. A
concise synthesis of chiral 2-methyl chroman-4-ones: Stereo selective
build-up of the chromanol moiety of anti-HIV agent, calanolide A.
Tetrahedron Lett. 1994, 35, 6347-6350.
(22) Howe, A. Y.; Bloom, J.; Baldick, C.; Christophers, J.; Cheng, H.-
M.; Christensen, J. S.; Chunduru, S. K.; Coburn, G. A.; Feld, B.;
Gopalsamy, A.; Gorczyca, W. P.; Herrman, S.; Johann, S.; Jiang,
X.; Kimberland, M. L.; Krishnamurthy, G.; Olson, M. W.; Orlowski,
M.; Swanberg, S.; Thompson, I.; Thorn, M.; Del Vecchio, A. M.;
Young, D. C.; van Zeijl, M.; Ellingboe, J. W.; Upeslacis, J.; Collett,
M. S.; Mansour, T. S.; O’Connell, J. Indentification of a novel non-
nucleoside inhibitor of hepatitis C virus RNA-dependent RNA
polymerase. Antimicrob. Agents Chemother. 2004, 48, 4813-
4821.